

# ***Biological and Pharmaceutical Bulletin***

## **Instructions to Authors**

Effective from January 1st 2024

*Biological and Pharmaceutical Bulletin* is published by the Pharmaceutical Society of Japan on behalf of its >15,000 members. Recent redevelopment initiatives are working consistently towards the journal's primary aim of advancing the pharmaceutical sciences worldwide. *Biological and Pharmaceutical Bulletin* publishes original, innovative articles from international authors for a large global audience, who openly access the journal online at the J-STAGE platform.

### **Guide to Contents**

Aims & Scope .....	1
How To Submit .....	1
Article Type Specifications .....	1
Manuscript Preparation .....	2
Scientific Policies .....	3
General and Editorial Policies .....	5
Publishing Model .....	8
Post-Acceptance Process .....	9
Contact Details .....	9

### **Aims & Scope**

*Biological and Pharmaceutical Bulletin* is an international, open access, peer-reviewed journal that publishes significant and novel contributions on biological aspects of the pharmaceutical and health sciences. Articles can take basic, experimental, applied or clinical approaches; the journal especially welcomes articles that present work at the interface of these areas. Article types include Regular Articles, Communications, Notes, and Reviews.

The journal covers a broad range of topics spanning the environmental, biological, molecular and microbiological aspects of the pharmaceutical sciences. Articles on applied clinical pharmaceuticals and the biological aspects of the chemistry of pharmaceutical science are also welcomed.

The journal is supported by the Pharmaceutical Society of Japan, which aims to advance the pharmaceutical sciences worldwide. *Biological and Pharmaceutical Bulletin* therefore provides its global authors with rapid but full peer-review services to select original, innovative, important work that is of the highest interest. A global audience of researchers, clinicians and pharmacists frequently access the journal's articles, which are available openly and freely online as soon as they are published.

### **How To Submit**

Authors from around the world are welcome to contribute to the journal. All manuscripts must be submitted *via* the journal's submission site at <https://www.editorialmanager.com/cpb-bpb/>.

Original and revised manuscript texts may be uploaded as a Word, Excel, PowerPoint or PDF file, but a Word file is preferable and required for the final manuscript text. Figures can be incorporated in the Word file, or can also be submitted separately in several other standard formats, except the ChemDraw format. These files are automatically incorporated into a single PDF that the system creates for review.

If you encounter any problems with your submission, please contact the Editorial Office at [ronb\(at\)pharm.or.jp](mailto:ronb(at)pharm.or.jp).

### **Article Type Specifications**

The Journal publishes Regular and Invited Reviews, Regular Articles, Communications, and Notes.

**Regular Reviews** are critical overviews of scientific discoveries in areas of the authors' expertise. These reviews are expected to include the authors' own recent interesting and significant results.

**Invited Reviews** are overviews of important topics that encompass recent scientific discoveries of high interest and significance. They are invited by the Editorial Board.

**Regular Articles** present original research performed by the authors and must include new data, analyses or information that is of significance and interest to a broad audience.

**Communications** are shorter articles that demand rapid publication due to the novelty, importance and immediate interest to the journal's readership. Authors must justify the need for urgent publication in a statement in their cover letter. In general, the main text of a **Communication** should not exceed 2000 words (approximately 4 journal pages).

**Notes** describe new facts and important data derived from work that is incomplete or only able to be partially completed. In general, the main text of a **Note** should not exceed 2000 words (approximately 4 journal pages).

## Manuscript Preparation

### Cover Letter

A cover letter must be included and should provide a brief overview of the work, its significance and the justification for publishing it. Authors who suggest potential referees should declare any relevant former or ongoing relationships in their cover letter. When submitting a Communication or Note, authors should provide the word count of the main text (including references) in their cover letter.

### Style and Format

Please use 12-point Times New Roman font, preferably in Word. All files should have a page setup for A4 (210 mm wide × 297 mm high) paper when printed. Tables can be presented horizontally if necessary.

### Title Page

The first page must be a Title page and should include the journal name (*Biol. Pharm. Bull.*) and manuscript type. This should be followed by the manuscript title, name(s) of the author(s), affiliation(s), and mailing address(es). The full address together with the telephone and fax numbers and e-mail address of the corresponding author should be given in a footnote. An asterisk (\*) should be added to the right of the corresponding author's name. Use a dagger (†) to the right of a name if the present affiliation of an author is different to their affiliation when the work was completed. Include the author's current affiliation and address in the footnote.

### Authors and Affiliations

The full names of authors and their affiliations must be provided. If authors have more than one affiliation, this should be indicated by italicized superscripts *a*, *b*, *c*... placed after the author's name, as shown below.

Hanako Yakugaku,<sup>*a,b*</sup> John Smith,<sup>*c*</sup> and Taro Soyaku<sup>*b*</sup>

Affiliations and addresses should then be provided as shown:

<sup>*a*</sup>*Department of Molecular Biology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan:*

<sup>*b*</sup>*Department of Pharmaceutical Services, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan: and*

<sup>*c*</sup>*Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 350-8566, Japan.*

### Summary and Keywords

On the second page, provide a Summary (<250 words) and 3 to 6 descriptive keywords in decreasing order of importance. As the keywords are used in combination to construct a rich and comprehensive index, they should be conceptually unrelated and should not repeat words or phrases. For example, using the keywords 'protein,' 'protein synthesis' and 'synthesis' together is not suitable. Abbreviations should not be used as keywords.

### Graphical Abstracts

Graphical abstracts are presented in the Table of Contents and other materials to give readers an at-a-glance grasp of the manuscript. Graphical abstracts consist of clear images, charts, graphs, chemical structures, or other informative illustrations that show the most striking feature of the article in visual form. Upon first submission, a full-color figure in the actual size to be used for the graphical abstract, no larger than 100 mm wide × 40 mm high with a resolution of 300 dpi (1181 × 472 pixels), should be provided.

Do not include proprietary logos, images, or product names in the figure.

### Main Text

The main body of the article should initially provide the Introduction, and then sections detailing the Materials and Methods, Results, and Discussion, in that order. Following these sections should be (in this order) Acknowledgments, Conflict of Interest, Supplementary Materials (if relevant), References, and Figure Legends.

## Tables and Figures

Tables should be presented after the main text, numbered with consecutive Arabic numerals, and headed by brief titles. We recommend using the ‘Tables’ feature in Word; do not paste tables as pictures. Any footnotes must be placed directly after the table.

Figures should be presented after the Tables section and numbered with consecutive Arabic numerals followed by a brief title. The figure number and title should be placed below the figure. In the main text or elsewhere, figures should be cited as “Fig. XX” within a sentence or “Figure XX” at the start of a sentence.

## Supplementary Materials

Authors can provide Supplementary Materials if they enhance the overall usefulness of the article and are relevant to more fully understanding or utilizing the article. Any Supplementary Materials should be submitted as separate document(s). In addition, text should be added between the Conflict of Interest and References sections that states: “This article contains Supplementary Materials.”

## Additional Information for Review

Other data necessary for peer review, including related manuscripts submitted elsewhere, should be submitted as additional information in separate documents, but labeled “Additional Information”. These materials will not be published in the journal.

## References

The journal’s definition of a reference is any article or chapter published in journals, books, and other outlets such as technical reports, patents, and lectures. References to any other materials or personal communications should be described in the text.

The journal uses a modified Vancouver referencing style. As such, references should be numbered consecutively according to the order of citation in the main text (one Arabic number should be assigned to each reference). An Arabic number followed by a right-hand half-parenthesis should be placed after the last relevant word in the sentence, outside any punctuation mark.

For example: “LAMP proteins are reported to be involved in lysosome-phagosome fusion.<sup>1)</sup>”

A maximum of two names should be listed when referring to authors in the main text, for example “Jones and Smith.” When referring to three or more authors, provide only the last name of the first author followed by *et al.* For example: “Jones *et al.*”

The References section collates the references cited in numerical order. Journal abbreviations should conform to those listed in PubMed. For all listed authors, the last name and all initials should be used as exemplified below.

- 1) Vasievich EA, Chen W, Huang L. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. *Cancer Immunol. Immunother.*, **60**, 629–638 (2011).
- 2) Shimizu K, Oku N. Brain tumor diagnosis using PET with angiogenic vessel-targeting liposomes. *Tumors of the central nervous system.* (Hayat MA ed.) Vol. 3, Springer, New York, pp. 169–176 (2011).
- 3) Brunner A, Greune H, U.S. Patent 1910462 (1993) [*Chem. Abstr.*, **27**, 4092–4096 (1993)].
- 4) International Organization for Standardization. “How ISO develops standards.”: <<https://www.iso.org/developing-standards.html>>, accessed 25 August, 2018.

## Scientific Policies

### Studies on Natural Products

Submissions that report on natural products (NPs) and/or crude extract materials (CEMs) from natural products must separately include a complete description and information on the sources of the NP/CEM, the extraction methods for the CEM, and elucidation standard in pharmacological studies of the NP/CEM. The full requirements can be found in “Guidelines for NP/CEM” at <https://bpb.pharm.or.jp/>.

All manuscripts must conform to the journal’s guidelines and standards. This holds for any submission reporting on CEMs prepared from NPs using Traditional Herbal Medicine formulae, such as Kampos or Traditional Chinese Medicine protocols.

### X-ray Crystal Structure Analyses

When structural determination by X-ray crystallographic analysis is a central part of a paper, the data should be attached as Supplementary Material and must be registered and deposited with the Cambridge Crystallographic Data Centre (CCDC). When crystallographic analysis plays only an accompanying role, the crystal data (including unit cell parameters, space group, Z density) as well as the R-factor must be reported. While not a requirement, the journal advises that the data be registered with the CCDC. Various descriptive data will only be published in the final article if they are important to the article’s overall rigor. These include: atomic coordinates when the structure is important; bond lengths and angles; thermal parameters; and torsion angles.

### ***Nucleotide Sequences***

Newly reported nucleotide sequences must be deposited in the DDBJ, GenBank, or EMBL Nucleotide Sequence Database. An accession number must be obtained before the manuscript can be accepted by the journal. Access to the information in the database must be available at the time of publication. The accession numbers of newly reported nucleotide sequences should be noted in Materials and Methods.

### ***Spectral and Elemental Analysis Data***

Please report spectral and elemental analysis data in the following format.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.25 (3H, d, *J*=7.0Hz), 3.55 (1H, q, *J*=7.0Hz), 6.70 (1H, m); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ: 20.9 (q), 71.5 (d), 169.9 (s); IR (KBr) cm<sup>-1</sup>: 1720, 1050, 910; UV λ<sub>max</sub> (EtOH) nm (ε): 241 (10860), 288 (9380); UV λ<sub>max</sub> (H<sub>2</sub>O) nm (log ε): 280 (3.25); FAB-MS *m/z*: 332.1258 (Calcd for C<sub>18</sub>H<sub>20</sub>O<sub>6</sub>: 332.1259); MS *m/z*: 332 (M<sup>+</sup>), 180, 168. [α]<sub>D</sub><sup>25</sup> -74.5 (*c*=1.0, MeOH); *Anal.* Calcd for C<sub>19</sub>H<sub>21</sub>NO<sub>3</sub>: C, 73.29; H, 6.80; N, 4.50. Found: C, 73.30; H, 6.88; N, 4.65.

### ***Nomenclature***

The nomenclature used for chemical compounds must be in accordance with IUPAC's published guidelines. Alternatively, naming may conform to the nomenclature in the index of *Chemical Abstracts* or the Ring Index. The nomenclature style must be internally consistent within the manuscript.

### ***Abbreviations***

Abbreviations must be spelled out in full and followed by the abbreviation in parentheses when first used in the Summary and in the main text. Thereafter, the abbreviation only should be used. Please limit to a minimum the use of abbreviations in the Summary and the Title.

Note that the following common abbreviations do not need to be defined:

ADP	adenosine 5'-diphosphate
AIDS	acquired immunodeficiency syndrome
AMP	adenosine 5'-monophosphate or adenylic acid
ANOVA	analysis of variance
ATP	adenosine 5'-triphosphate
cAMP	adenosine 3',5'-cyclic monophosphate
cDNA	complementary DNA
CoA	coenzyme A
CYP	cytochrome P450
DNA	deoxyribonucleic acid
ED <sub>50</sub>	50% effective dose
ESR	electron spin resonance
FAB-MS	fast atom bombardment mass spectrometry
FAD	flavin adenine dinucleotide
GC-MS	gas chromatography-mass spectrometry
GLC	gas-liquid chromatography
GMP	guanosine 5'-monophosphate
HPLC	high-performance liquid chromatography, high-pressure liquid chromatography
IC <sub>50</sub>	inhibitory concentration, 50%
IR	infrared
LC	liquid chromatography
LC/MS	liquid chromatography/mass spectrometry
LD <sub>50</sub>	50% lethal dose
mRNA	messenger RNA
MS	mass spectrum
NMR	nuclear magnetic resonance
OTC	over the counter
PCR	polymerase chain reaction
QOL	quality of life
RNA	ribonucleic acid
RT-PCR	reverse transcription polymerase chain reaction
TLC	thin-layer chromatography
tRNA	transfer RNA
UV	ultraviolet

**Units**

The following units should be used:

length	m, cm, mm, $\mu\text{m}$ , nm, Å
mass	kg, g, mg, $\mu\text{g}$ , ng, pg, mol, mmol, $\mu\text{mol}$
volume	L, mL, $\mu\text{L}$
time	s, min, h, d
temperature	°C, K
radiation	Bq, dpm, Gy, Sv
concentration	M, mM, mol/L, mmol/L, mg/mL, $\mu\text{g/mL}$ , %, % (v/v), % (w/v), ppm, ppb

**General and Editorial Policies**

Authors should carefully read the journal policies below, as submission to *Biological and Pharmaceutical Bulletin* implies that all authors have read and approved these policies. Authors are encouraged to consult commonly accepted policy standards, which the journal supports, such as those presented by the Council of Science Editors or the International Committee of Medical Journal Editors (ICMJE). Submission to *Biological and Pharmaceutical Bulletin* also implies that all authors have seen and approve the manuscript, agree to its submission and have the right to publish the work, and that it is not defamatory or libelous. All authors also undertake that the manuscript is original and has not been published elsewhere in any language, nor is otherwise under consideration at another journal. Authors must inform the editors if any related publications have been submitted or are in press elsewhere.

**Acceptance Criteria**

The Instructions to Authors refers to various basic acceptance criteria, including that manuscripts must fall within the journal's scope, as well as requirements for ethical behavior, compliance with human or animal experimentation policies, data policies, various technical requirements, English standard, copyright provisions, and so forth. In addition, articles in the journal must also be:

- scientifically rigorous
- novel, innovative and/or original
- important, or potentially important, to the progress of the field and the researchers within it
- constructed, written and/or placed in an appropriate context so as to be of the highest possible interest to a broad international audience.

**Authorship**

Contributors to *Biological and Pharmaceutical Bulletin* should meet the following criteria for authorship. All authors must:

- agree to be held accountable for all aspects of the work
- have made a substantial contribution to the work's conception or design, or in the acquisition, analysis or interpretation of data
- have written the manuscript or critically revised it for vital intellectual content
- have approved the final version of the manuscript for publication.

By submitting to the journal, the authors undertake that they have agreed to the author list and its order. Any changes to the author list (such as author order, or adding or removing authors) after peer review will rarely be approved by the journal. If requests are made, they must have strong justification and be approved by all the listed authors.

**Human/Animal Experimentation**

For submissions that include investigations with human subjects and/or human tissues, the authors must declare that the work was performed in accordance with the ethical principles for medical research outlined in the Declaration of Helsinki 1964 and per subsequent revisions. In addition, relevant manuscripts must contain a statement confirming that approval was received prior to the study's commencement from the appropriate ethics committees. The declaration should be clearly stated in Materials and Methods.

For submissions that include animal experimentation, the authors must declare within the manuscript that the work was performed in accordance with the experimental animal guidelines of the authors' institutions. In addition, appropriate government guidelines should be followed and these should be cited in the declaration; standards must meet those as set out in and published in, for example, the Japanese Ministry of Education, Culture, Sports, Science and Technology. The declaration should be clearly stated in Materials and Methods.

### ***Unoriginal Material***

Authors warrant that their submissions are original works. The journal uses iThenticate<sup>®</sup> software to screen submitted manuscripts for unoriginal material, and submission to the journal implies that authors agree to this process. The journal reserves the right to return a manuscript for no further consideration if it is found to contain an unacceptable amount of unoriginal material. Resubmitted manuscripts will be considered only if the unoriginal material has been removed.

### ***Preprint Policy***

Posting of manuscripts to a community nonprofit preprint server by the author does not preclude consideration for publication. Authors who post their work as a preprint should identify the preprint server and include the accession number or digital object identifier (DOI) in their cover letter. If a manuscript is accepted for publication in the journal, authors should update the preprint to include the journal reference (including DOI) and a link to the published article on *Biological and Pharmaceutical Bulletin* website.

### ***Data Falsification, Data Fabrication and Image Integrity***

Authors must not falsify or fabricate data. The journal conforms to high standards in the presentation of images. Digital manipulation or processing of images is permitted, but all figures must accurately reflect the underlying data. The editors may request original data and images from the authors either before or after publication, as necessary.

### ***Use of Copyrighted Material***

Use of any figures or other previously published material for which the authors do not own or have rights to is only possible if the authors obtain permission from the copyright owner and provide relevant documentation stating this upon submission of the manuscript.

### ***Data and Materials Availability***

The journal supports initiatives that improve the undertaking and outcomes of research. By submitting to the journal, authors agree to make their submission's materials, data and any protocols available in response to reasonable requests for it.

The journal supports the use of Supplementary Materials for data and relevant materials, or the use of relevant and accepted public repositories. See the Supplementary Materials section for further details on the format and style for these materials. Please also refer to the relevant parts of the Scientific Policies section within this document.

### ***J-STAGE Data***

Data associated with the manuscript can be published at J-STAGE Data, if both the manuscript and data are accepted for publication. Authors who wish to submit their data should contact the Editorial Office at ronb(at)pharm.or.jp for instructions. All data and datasets submitted for potential publication are peer-reviewed by the Editorial Board; only those accepted are published. Copyright within the data is retained by the author and published under the Creative Commons BY-NC (4.0) International license.

### ***Conflicts of Interest***

A conflict of interest exists when someone has financial or personal relationships that could inappropriately influence (bias) consideration or publication of a submitted manuscript. The journal has strong policies for conflicts of interest among editors, referees, editorial board members and staff, and authors.

Authors should refer to and comply with the Council for Science Editors' policies, which cover personal, financial and non-financial conflicts of interest. Further, any relevant financial relationship of any author with any company or institution that might benefit from the publication of the manuscript must be disclosed.

Authors should consider the following as a guide for financial disclosures:

1. Research funding from a for-profit (commercial) organization
2. Consulting fees/honoraria
3. Patent royalties/licensing fees
4. Employment/leadership positions or advisory roles
5. Other (travel fees, gift, *etc.*)

A disclosure must be included in the main text of the manuscript in the Conflict of Interest section. If the authors have no conflict of interest, they must state as much:

“The authors declare no conflict of interest.”

If one or more authors have some conflict of interest, it must be stated, for example:

A (author name) received a research grant from O (entire company, institute or personal name); B received non-financial support from P; C serves as a consultant to Q; D received honoraria for writing promotional material for R; E has a patent JP Patent 12345 licensed to S; F is President of T; G has been reimbursed by U for attending conferences; H and I are

employees of X; J has no conflict of interest.

### ***Confidentiality***

All manuscripts that are under consideration, or have been returned to authors, are kept confidential. Authors agree to keep in confidence all correspondence about their submission from the journal, editors and Editorial Office.

The journal undertakes single anonymized peer review, and referees' identities will not be disclosed unless formally and explicitly requested by the referee. Referees agree to maintain the confidentiality of submitted manuscripts as part of their agreement to review articles for the journal.

### ***Editorial and Peer Review Process***

The journal is organized into eight broad subject areas and each area has a Section Editor-in-Chief who is supported by several Handling Editors. The journal is supported by over 80 Handling Editors who are experts in specific areas across the journal's broad remit. Handling Editors are responsible for the peer-review process, that is, selecting and communicating with referees and making the initial and final decisions on manuscripts. Section Editors-in-Chief assign the relevant Handling Editor and have an oversight role as necessary. The journal's Editor-in-Chief has responsibility for the overall strategy of the journal and acts as a final arbiter when necessary.

The assigned Handling Editor undertakes single anonymized peer review, which is undertaken after initial screening by the Editorial Office, Section Editor-in-Chief and Handling Editor. Manuscripts clearly not conforming to the basic requirements or acceptance criteria of the journal, as outlined in these instructions, will be returned to the authors without peer review.

With the exception of Invited Reviews (which are reviewed by an Editor-in-Chief or Editor(s)), manuscripts that pass through initial screening are sent to two or more referees, who provide feedback and their opinion about the suitability of the manuscript for publication. Referees are selected on the basis of their expertise, reputation and previous experience as peer reviewers. To ensure that the journal obtains the best advice within the context of its requirements, referees are provided with a Guide to Referees that includes the journal's acceptance criteria.

The Handling Editor uses the referees' reports as the basis of their initial decision, which can be minor revision, major revision, or reject. Authors are invited to re-submit a revised version in the former two cases; for some manuscripts, a round of re-review may be deemed necessary. After revision, articles that are deemed to fulfil the journal's requirements are accepted for publication.

Revised manuscripts must be re-submitted no later than two months from the date of notification of manuscript revision by the Handling Editor. Manuscripts that are not re-submitted within two months may be rejected and have to be re-submitted as new manuscripts (which invokes a further submission fee). Authors should contact the journal if they are unable to re-submit within the required deadline.

### ***Referee Suggestions***

Authors may suggest potentially suitable referees *via* Editorial Manager; these referees must be qualified experts who are able to provide timely advice. Authors must declare any ongoing or former relationships with suggested referees in the cover letter. Authors can also request that potential referees be excluded. The journal may consider these requests but is under no obligation to honor them; the Editors have complete discretion over the selection of referees.

### ***Editorial Independence and Conflicts of Interest***

The Pharmaceutical Society of Japan has granted the journal's Editorial Board complete and sole responsibility for all editorial decisions. The Society will not become involved in editorial decisions, except in cases of a fundamental breakdown of process.

Editorial decisions are based only on a manuscript's scientific merit and are kept completely separate from the journal's other interests. The authors' ability to pay any publication charges has no bearing on whether a manuscript is accepted for publication in the journal.

Reviewers and members of the journal's Editorial Board undertake to declare any conflicts of interest when handling manuscripts. An editor or reviewer who declares a conflict of interest is unassigned from the manuscript in question and is replaced by a new editor or reviewer.

Editors try to avoid conflicts of interest when inviting reviewers, but it is not always possible to identify potential bias.

### ***Appeals***

The journal will consider appeals that provide specific evidence of misunderstanding, mistake or error by a referee or editor. An appeal is considered by the relevant Editors, whose decision is final.



### ***Errata and Retractions***

The journal supports the maintenance of an accurate record of science and hence will correct any significant errors in the journal. If authors discover a significant error or inaccuracy in their published article, they should promptly notify the Editor-in-Chief. The Editor-in-Chief will also assess any third-party advice independently received and, in both cases, determine whether an Erratum or a Retraction is appropriate.

Errata describe errors that significantly affect the scientific integrity of an article or the reputation of the journal or authors. Retractions are used when the results or conclusions are found to be invalid or misleading, or when there is sufficient evidence of breaches in research or publication ethics. Minor errors that are the result of the authors' actions will not be amended. If the authors, or some co-authors, do not agree to a correction being published, the journal reserves the right to publish an Erratum or Retraction that will separately list the dissenting co-authors. The journal's decision in these matters is final.

### ***English Standard***

Only manuscripts written in clear, concise English will be accepted for peer review. Authors who are not native English speakers should have their manuscripts checked and edited by a native English speaker who possesses sufficient scientific knowledge. If the English standard of an accepted manuscript is judged to be inadequate by the journal, two options are possible. 1) Authors may utilize a trusted service provider and provide a certificate of editing or 2) Authors may utilize the journal's service provider, whose costs will be passed on (see the charges section below). The Editorial Office coordinates this process upon acceptance of a manuscript.

### ***Self-archiving (Green Open Access) Policy***

Self-archiving, also known as Green Open Access, enables authors to deposit a copy of their manuscript in an online repository. Authors of original research manuscripts submitted to the journal before January 1st, 2024 may upload their article to their institutional repository immediately after publication in the journal; permission is required for other locations. For articles submitted to the journal after January 1st, 2024, authors of original research manuscripts may upload their article to any repository. In all cases, suitable attribution to the published article in journal should be included.

### ***Long-Term Digital Archiving***

J-STAGE preserves its full digital library, including the journal, with Portico in a dark archive (see <https://www.portico.org/publishers/jstage/>). In the event that the material becomes unavailable at J-STAGE, it will be released and made available by Portico.

## **Publishing Model**

From January 1st, 2024, the journal will introduce open licensing for its articles. Material submitted from this date can be non-commercially used or reused without prior permission in ways defined by the Creative Commons license detailed below.

To recoup costs and fund its development, the journal charges a submission fee and accepted manuscripts are subject to Article Processing Charges. Reprints are available to those who choose to purchase them, and the costs and procedures are detailed below. Publication is dependent on the payment of relevant charges.

### ***Copyright and Licensing***

From January 1st, 2024, authors will be required to provide the Pharmaceutical Society of Japan with a License to Publish their work; authors retain their copyrights and agree to publish their work under a Creative Commons Attribution-NonCommercial- 4.0 International license (CC BY-NC 4.0). This license allows users to share and adapt an article, non-commercially, as long as appropriate credit is given. The authors must submit a License to Publish form to the Society before the article will be published.

The copyright in articles in *Biological and Pharmaceutical Bulletin* submitted before January 1st, 2024 belongs to the Pharmaceutical Society of Japan. Authors may re-use their figures/tables of these articles without further permission as long as the article is properly referenced and attributed. All other users of this material must seek permission from the journal by contacting the Editorial Office (see the Contact section for details).

### ***Publication Fees***

#### **Submission Fee**

A one-time fee of JPY 3000 per manuscript, payable by credit card, is charged to authors of all new submissions.

#### ***Article Processing Charges (APCs)***

The journal charges APCs for all accepted articles except Invited Reviews, which are free to publish. The APCs (JPY) are listed in the table below. To be eligible for the Members price, the corresponding author must be a member of the Pharmaceutical Society of Japan at the APC invoice date. The Members price is not applicable for Supporting members (corporate members). Authors of accepted manuscripts will be invoiced for the APC before publication of their manuscript.



	Members (JPY)	Non-members (JPY)
Regular Articles, Regular Reviews	60000	90000
Communications, Notes	40000	60000

### **English Editing**

If authors utilize the journal's English editing services, the actual costs borne by the journal, plus an administration fee (15% of the cost), will be passed on to the authors. Please see the English Standard section within this document for more details.

### **Reprint Charges**

Reprints are available only in multiples of 50. If you choose to have color reprints, note that color printing carries an extra surcharge of JPY 80 per page. If you would like a cover on each reprint, the charge is JPY 30 per cover. Postage is included in the prices below.

Number of Pages Number of Reprints	1-2	3-4	5-6	7-8	9-10	>10
	Charge (JPY)					
50	8000	9000	10000	11000	12000	13000
100	14400	16200	18000	19800	21600	23400
150	19200	21600	24000	26400	28800	31200
200	22400	25200	28000	30800	33600	36400
250 or more	110 each	120 each	130 each	150 each	160 each	180 each

### **Changes to Fees**

The journal reserves the right to modify the charges without prior notification.

### **Post-Acceptance Process**

Authors notified of the acceptance of their manuscript will be provided with information and forms that facilitate its publication. After an average of approximately 30 days after acceptance, authors will be provided proofs of their typeset article. No additions or revisions are allowed, except to correct typographical errors introduced during the production process. Correcting any author-derived errors may lead to extra administrative charges.

All articles are published continuously online in an Article-Based Publication model. When published, articles are open and freely available online in full text HTML and PDF at the journal's J-STAGE site at <https://www.jstage.jst.go.jp/browse/bpb/>.

### **Contact Details**

#### **Editorial Office**

**Email:** ronb(at)pharm.or.jp

2-12-15 Shibuya, Shibuya-ku, Tokyo 150-0002, Japan

**FAX:** +81-3-3498-1835

Online ISSN : 1347-5215